Presentations and Publications
Read about publications and presentations made by Benitec's scientific team below. For details of Benitec's announcements to NASDAQ, read details in our Investor Centre.2016
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
ASGCT 19th Annual Meeting, Washington DC
May 5, 2016
A comparison of scAAV8-TT034 mediated transduction and shRNA expression in human liver biopsy samples versus a chimeric mouse model with humanized liver
ASGCT 19th Annual Meeting, Washington DC
May 5, 2016
BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo
ASGCT 19th Annual Meeting, Washington DC
May 5, 2016
Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)
ASGCT 19th Annual Meeting, Washington DC
May 5, 20162015
Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)
The Liver Meeting (AASLD), San Francisco
Nov 14, 2015
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
The Liver Meeting (AASLD), San Francisco
Nov 13, 20152012
In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy
Antimicrobial Agents and Chemotherapy. 2012; 56(3):1364-1375. doi:10.1128/AAC.05357-11
Jan 1, 2012
Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model
Molecular Therapy. 2012; 20(9):1737-1749. doi:10.1038/mt.2012.119
Jan 1, 2012